BrightGene Bio-Medical Technology Company Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
559
- Stock Symbol
-
688166
- Investments
-
8
- Share Price
-
$4.97
- (As of Thursday Closing)
BrightGene Bio-Medical Technology Company General Information
Description
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
Contact Information
- Building C25-28
- No. 218 Xinghu Road, SIP
- Suzhou, Jiangsu 215011
- China
BrightGene Bio-Medical Technology Company Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.97 | $5.03 | $2.43 - $6.53 | $2.1B | 422M | 21.6M | $0.08 |
BrightGene Bio-Medical Technology Company Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 1,929,148 | 1,519,297 | 2,439,970 | 2,828,231 |
| Revenue | 164,439 | 151,062 | 162,985 | 113,682 |
| EBITDA | 39,822 | 46,647 | 47,659 | 30,991 |
| Net Income | 33,145 | 35,581 | 37,780 | 24,590 |
| Total Assets | 680,599 | 675,615 | 465,888 | 279,765 |
| Total Debt | 295,121 | 293,022 | 141,576 | 33,688 |
BrightGene Bio-Medical Technology Company Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BrightGene Bio-Medical Technology Company Comparisons
Industry
Financing
Details
0000 0
000000
BrightGene Bio-Medical Technology Company Competitors (21)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mapi Pharma | Venture Capital-Backed | Ness Ziona, Israel | 00 | 00000 | 0000000000 0 | 00000 |
| 000000000000 | Private Equity-Backed | Plankstadt, Germany | 0000 | 000000000000 | ||
| 000000 00000000000 | Formerly PE-Backed | South San Francisco, CA | 00 | 00000 | 000000&0 | 00000 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
BrightGene Bio-Medical Technology Company Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Yuan Zou | Chief Financial Officer | ||
| Richard Chan | Marketing Director | ||
| Jiandong Yuan | Founder, Chairman & General Manager |
BrightGene Bio-Medical Technology Company Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jiandong Yuan | BrightGene Bio-Medical Technology Company | Founder, Chairman & General Manager | 000 0000 |
| Yi Shi Ph.D | Self | Board Member | 000 0000 |
BrightGene Bio-Medical Technology Company Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BrightGene Bio-Medical Technology Company Investments (8)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Annuo Bode | 03-Apr-2023 | 00000 0000 | Biotechnology | ||
| Particella | 01-Apr-2022 | 00000 0000 | 00.00 | Drug Discovery | |
| Phaeno Thera | 31-Aug-2021 | 00000 0000 | 000.00 | Drug Discovery | |
| Lychix | 18-Dec-2020 | 00000 0000 | Biotechnology | ||
| GeneQuantum Healthcare | 19-Nov-2020 | Later Stage VC | Biotechnology |
BrightGene Bio-Medical Technology Company ESG
Risk Overview
Risk Rating
Updated October, 01, 2023
26.01 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Biotechnology
Subindustry
00 of 399
Rank
Percentile
